Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, United Kingdom
Medicine Health Service, Michael Garron Hospital, Toronto, Ontario, Canada; and Daphne Cockwell School of Nursing, Toronto Metropolitan University, Toronto, Ontario, Canada.
Respir Care. 2024 Jul 24;69(8):946-952. doi: 10.4187/respcare.11396.
Health care costs attributed to COPD have been estimated at $4.7 trillion globally in the next 30 years. With the global burden of COPD rising, identification of interventions that might lead to health care cost savings is an imperative. Although many studies report the effect of COPD self-management interventions on subject outcomes and health care utilization, few data describe their effect on health care costs.
Using data linkage and established case-costing methods with provincial Canadian health databases, we established public health care costs (acute and community) for 12 months following randomization for the 462 participants enrolled in our randomized controlled trial of the Program of Integrated Care for Patients with COPD and Multiple Comorbidities.
Total median (interquartile range) in-hospital costs in the 12 months follow-up for all (intervention and control) 462 trial participants were CAD $4,769 ($417-16,834) (equivalent to US $3,566 [$312-12,588]). Total costs incurred in the community were higher at CAD $8,011 ($4,749-13,831) (equivalent to US $5,990 [$3,551-10,342]). Controlling for sex, income quintile, Johns Hopkins Aggregated Diagnosis Groups score, and living in an urban locality, we found lower community health care costs but no differences in acute care costs for participants receiving our multicomponent COPD exacerbation prevention management intervention compared to usual care.
Controlling for important confounders, we found lower public community health care costs but no difference in acute health care costs with our multicomponent COPD exacerbation prevention management intervention compared to usual care. Community health care costs were almost double those incurred compared to acute health care costs. Given this finding, although most COPD exacerbation management interventions generally focus on reducing the use of acute care, interventions that enable health care cost savings in the community require further exploration.
据估计,未来 30 年内,全球因 COPD 导致的医疗保健费用将达到 4.7 万亿美元。随着 COPD 全球负担的增加,确定可能导致医疗保健成本节约的干预措施至关重要。尽管许多研究报告了 COPD 自我管理干预对患者结局和医疗保健利用的影响,但很少有数据描述其对医疗保健成本的影响。
我们使用数据链接和加拿大省级卫生数据库中既定的病例成本计算方法,为我们的 COPD 和多种合并症患者综合护理计划随机对照试验中纳入的 462 名参与者,确定了随机分组后 12 个月内的公共医疗保健成本(急性和社区)。
所有(干预组和对照组)462 名试验参与者在 12 个月随访期间的住院总中位数(四分位距)费用为 4769 加元(417-16834)(相当于 3566 美元[312-12588])。社区总费用更高,为 8011 加元(4749-13831)(相当于 5990 美元[3551-10342])。在校正性别、收入五分位数、约翰霍普金斯综合诊断组评分和居住在城市地区后,我们发现,与常规护理相比,接受我们的多组分 COPD 加重预防管理干预的患者的社区医疗保健费用较低,但急性护理费用没有差异。
在控制重要混杂因素后,与常规护理相比,我们发现多组分 COPD 加重预防管理干预可降低社区公共医疗保健成本,但急性医疗保健成本没有差异。社区医疗保健成本几乎是急性医疗保健成本的两倍。考虑到这一发现,尽管大多数 COPD 加重管理干预通常侧重于减少急性护理的使用,但需要进一步探索能够在社区实现医疗保健成本节约的干预措施。